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OBJECTIVES The object of the present study is to determine whether native (n) low-density lipoprotein
(LDL) isolated from men with type II diabetes and abnormal endothelial function inhibits
endothelium-dependent relaxation more than n-LDL isolated from nondiabetic control
subjects.
BACKGROUND Endothelium-dependent vasodilation is impaired in men with type II diabetes and this may
result from qualitative rather than quantitative abnormalities of LDL.
METHODS Forearm blood flow responses to brachial artery infusions of acetylcholine (endothelium-
dependent vasodilator) and nitroprusside (endothelium-independent vasodilator) were mea-
sured in 10 men with uncomplicated type II diabetes and 10 nondiabetic men of similar age
and with similar plasma concentrations of LDL cholesterol. Native LDL was isolated by
discontinuous density gradient ultracentrifugation using EDTA to prevent oxidation.
Preconstricted rabbit aortic ring bioassay was used to determine inhibitory properties of
n-LDL on endothelium-dependent relaxation by measuring relaxation to acetylcholine (and
nitroprusside) in the presence and absence of n-LDL.
RESULTS Forearm blood flow responses to acetylcholine but not nitroprusside were significantly
impaired (p , 0.01) in diabetic men compared with control subjects. Native LDL (10 and
100 mg protein/ml) from diabetic men inhibited relaxation to acetylcholine by 13.9 6 4.8%
and 61.9 6 7.8% (mean inhibition for all doses 6 SE), respectively, whereas n-LDL from
control subjects inhibited relaxation by 7.3 6 3.0% and 23.9 6 5.7% (p , 0.01 for a difference
between diabetic and control n-LDL). Relaxation to nitroprusside was not significantly
inhibited by n-LDL.
CONCLUSIONS A qualitative abnormality of LDL may account for endothelial dysfunction in men with type
II diabetes. (J Am Coll Cardiol 2000;35:1622–7) © 2000 by the American College of
Cardiology
Atherosclerosis, the major cause of mortality in type II
(noninsulin-dependent) diabetes mellitus, is initiated by
injury to the endothelium (1). Low-density lipoprotein
(LDL) is thought to initiate such injury (1) and in hyper-
cholesterolemic subjects, dysfunction of the endothelium is
evident as impaired endothelium-dependent vasodilation
before the development of atherosclerosis (2). Endothelial
function is impaired in patients with type II diabetes even in
the absence of elevated LDL cholesterol (3,4). Physical
characteristics of LDL particles are altered in type II
diabetes and it has been suggested that this renders them
more atherogenic (5,6). Whether LDL from diabetic sub-
jects is more injurious to the endothelium is, however,
unknown. The purpose of the present investigation was to
determine the effect of native (n) LDL isolated from men
with type II diabetes, in whom endothelial function mea-
sured in vivo is abnormal, on endothelium-dependent va-
sorelaxation. To do this, we measured endothelial function
in vivo, isolated n-LDL from diabetic and healthy control
subjects and assessed its inhibitory effect on endothelium-
dependent relaxation using a bioassay.
METHODS
Men with type II diabetes (n 5 13), diagnosed on the
presence of symptoms plus fasting glucose levels .7.0
mmol/liter, were recruited from the Department of Endo-
crinology and Diabetes at St. Thomas’ Hospital. The
conditions of all diabetic men had been diagnosed at least
three months previously and were controlled by diet or by
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diet plus oral hypoglycemic therapy (5/13). None had
clinical evidence of atherosclerosis or of microvascular com-
plications other than mild background retinopathy. All had
urinary albumin/creatinine ratios within the normal range,
and none had evidence of neuropathy on vibration testing.
None were taking drugs other than oral hypoglycemic
agents. Control men (n 5 12) were recruited from hospital
staff. In vivo measurements of endothelial function and in
vitro effects of isolated LDL were each studied in 10
diabetic and 10 control subjects (some subjects were not
available for both measurements because timing was con-
strained by the need to use freshly prepared LDL). The
study protocol was approved by St Thomas’ Hospital
Research Ethics Committee and all subjects gave written,
informed consent. Subject characteristics are shown in
Table 1.
Lipid profiles and LDL subfractions. Serum total choles-
terol, triglycerides and high-density lipoprotein (HDL)
cholesterol levels were measured using standard enzymatic
methods. Levels of LDL cholesterol were calculated using
the Friedwald equation. The LDL subfractions in serum
frozen at the time of the study were later separated using
high resolution polyacrylamide gel electrophoresis (Li-
poprint LDL system; Quantimetrix; Redondo Beach, Cal-
ifornia) as previously described (7). This method identifies
seven LDL subfractions (LDL-0 to LDL-6) of increasing
density according to their relative electrophoretic mobility.
The major subfraction was identified as the most intense
band in a densitometric scan of the gel. In addition, the
subfraction distribution was quantitated using an LDL
score in which subfraction band (0 to 6) was multiplied by
the relative contribution of each subfraction to the total.
This score takes into account the relative proportions of
each subfraction, providing an index of LDL density, a
greater score being associated with smaller higher density
LDL (7).
Endothelial function in vivo. Forearm blood flow studies
were performed in a quiet clinical laboratory (temperature
controlled to between 24°C and 26°C during each study) in
the morning after a light breakfast. Treatment with oral
hypoglycemic drugs was omitted on the morning of the
study. The brachial artery was cannulated, and blood flow
was measured by venous occlusion strain gauge plethysmog-
raphy (8) during infusion of 0.9% saline or drugs dissolved
in saline at 1.0 ml/min. Following determination of basal
flow, blood flow was measured during infusions of three
cumulative doses (7.5, 15 and 30 mg/min) of acetylcholine
chloride (Coopervision; Southampton, United Kingdom)
and, after blood flow had returned to baseline, of sodium
nitroprusside (1, 3 and 10 mg/min, Roche; Basle, Switzer-
land). Each dose was infused for 6 min with blood flow
(mean of five venous occlusions) measured during the last
2 min of each infusion period. Blood pressure was measured
in supine position in triplicate using a vital signs monitor
(Dinamap model 1846 SX; Critikon; Tampa, Florida) at the
end of the study.
Preparation and characterization of LDL. Venous blood
was collected into specimen tubes (Vacutainers) containing
EDTA. Plasma was separated by low speed centrifugation
at 4°C and n-LDL (density, 1.019 to 1.063 g/ml) then
isolated from the plasma by discontinuous density gradient
ultracentrifugation (9). Isolated n-LDL was then dialyzed
with continuous stirring at 4°C for 24 h against two changes
of 10 mM phosphate buffer solution (pH 7.4). The protein
concentration was measured (10), and the final concentra-
tion of LDL was expressed as mg protein/ml. Freshly
prepared LDL was used within 24 h for the isolated rabbit
aortic ring studies described below. Oxidative modification
of LDL was prevented by the inclusion of 0.3 mM EDTA
in all buffers (11). Oxidation of LDL was sought by
measurement of thiobarbituric acid–reactive substances
(TBARS) (12). In each sample of isolated LDL, TBARS
were below the limit of detection, being ,1% of the value
obtained when the sample was oxidized by exposure to
Cu11 (CuSO4, 1.7 mM) for 3 h.
Abbreviations and Acronyms
ANOVA 5 analysis of variance
HDL 5 high-density lipoprotein
LDL 5 low-density lipoprotein
n-LDL 5 native LDL
NO 5 nitric oxide
TBARS 5 thiobarbituric acid–reactive substances
Table 1. Subject Characteristics
Control
Subjects
(n 5 12)
Type II
Diabetics
(n 5 13)
Age (yr) 50 (9) 47 (11)
BMI (kgzm22) 27 (8) 27 (5)
Systolic BP (mm Hg) 127 (12) 133 (15)
Diastolic BP (mm Hg) 76 (14) 80 (8)
Glucose (mmol/liter) 4.8 (1.3) 9.2 (4.7)*
HbA1c (%) 5.1 (0.4) 7.7 (2.4)*
Total cholesterol (mg/dl) 213 (34) 182 (35)
HDL cholesterol (mg/dl) 58 (19) 39 (8)*
Triglycerides (mg/dl) 151 (86) 177 (106)
LDL cholesterol (mg/dl) 112 (8) 124 (12)
Major LDL subfraction†
Band 0 5/10 4/10
Band 1 4/10 5/10
Band 2 1/10 1/10
*p , 0.01 compared with control subjects.
†The LDL subfractions measured in 10 control subjects and 10 diabetics in whom
LDL was isolated for in vitro studies.
BMI 5 body mass index; BP 5 blood pressure; HbA1c 5 glycosylated hemoglo-
bin; HDL 5 high density lipoprotein; LDL 5 low-density lipoprotein.
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Bioassay to determine inhibitory effects of isolated LDL
on endothelium-dependent relaxation. New Zealand
white male rabbits (2 to 2.5 kg) were sacrificed to obtain the
descending thoracic aorta, which was trimmed of adhering
tissue and fat. Paired transverse 2-mm-wide rings were cut
and mounted in 3-ml organ baths containing oxygenated
Krebs’ solution (1 0.3 mM EDTA), at 37°C. Tissues were
placed under 2g resting tension for 60 min and tension
adjusted to 2g for a further 30 min. Isometric measurements
were recorded via force transducers (Grass FT03; Grass
Inst; West Warwick, New York). Tissues were contracted
with increasing doses of norepinephrine (0.06 to 0.12 mM)
to determine a concentration that gave 80% maximum
contraction. Repeated exposure to this concentration was
performed to establish that reproducible contractions were
obtained. Relaxation dose-response curves to acetylcholine
chloride (1028 to 1026 M) were then obtained. Paired rings
were incubated with either patient or control n-LDL at two
concentrations of 10 mg protein/ml and 100 mg protein/ml
for 20 min; contraction/relaxation was then repeated.
Washout and relaxation of precontracted rings to acetylcho-
line were repeated between and after the two concentrations
of n-LDL to ensure that baseline responses were maintained.
Finally, after further washout, endothelium-independent re-
laxation to nitroprusside was examined in the presence and
absence of n-LDL (100 mg/protein/ml). The concentra-
tions of LDL used were chosen to be similar to those that
have been shown to have minimal inhibitory effects on
endothelium-dependent relaxation in this preparation,
when LDL is isolated from healthy volunteers (11).
Data analysis and statistical methods. Descriptive statis-
tics (Table 1) are summarized as means 6 SD. Results are
expressed as means 6 SE. Analysis of variance (ANOVA)
for repeated measures was used to test for differences in
forearm vasodilator responses and for an interaction be-
tween the dose response and group. Blood flow data were
log transformed prior to statistical analysis since the distri-
bution of values thus transformed more closely approxi-
mated a normal distribution. Repeated measures ANOVA
was also used to test for differences in inhibitory properties
of isolated n-LDL on endothelium-dependent relaxation.
In addition, the following summary measure of the inhibi-
tory effects of LDL on relaxation (R) was calculated from
the sum of the relaxations in the absence (S R) and presence
of LDL (S RLDL) to all doses of drug:
@~S R 2 S RLDL)/S R] 3 100%.
Differences were considered significant if p , 0.05.
RESULTS
Lipid profiles and distribution of LDL subfractions.
Serum concentrations of total cholesterol, LDL cholesterol
and triglycerides were similar in control and diabetic men.
High-density lipoprotein cholesterol level was significantly
lower in diabetic men than in control subjects (Table 1).
The distribution of major LDL subfractions was similar in
diabetic and control men (Table 1). The LDL subfraction
score was also similar in the two groups (1.7 6 0.2 vs. 1.6 6
0.2 for diabetic and control subjects, respectively).
Endothelial function in vivo. During each blood flow
study, blood flow in the noncannulated control arm did not
change significantly in response to drug infusions in the
contralateral arm, indicating that, at the doses used, these
drugs had no systemic effects. Mean blood flow in the
cannulated arm during infusion of acetylcholine and nitro-
prusside is shown in Figure 1. Blood flow responses to
acetylcholine were significantly lower in men with type II
diabetes compared with control men (Fig. 1, p , 0.01). The
highest dose of acetylcholine increased forearm blood flow
to 12.7 6 1.9 ml/min per 100 ml forearm in control men
and to 7.4 6 1.0 ml/min/100 ml in men with type II
diabetes. Blood flow responses to nitroprusside were similar
in control and diabetic men.
Inhibitory effects of isolated LDL on endothelium-
dependent relaxation. The effect of n-LDL (100 mg pro-
tein/ml) from the diabetic and control subjects on acetyl-
choline induced relaxation of the preconstricted rabbit aortic
ring bioassay is shown in Figure 2. The n-LDL from
diabetic subjects inhibited relaxation to a greater extent than
did n-LDL from control men (p , 0.01 by ANOVA for
repeated measures). The n-LDL (10 and 100 mg protein/
ml) inhibited relaxation to acetylcholine in a dose-
dependent manner (p , 0.01, Fig. 3), with n-LDL from
men with type II diabetes being significantly more potent
than n-LDL from control men (percent inhibition: 61.9 6
7.8% vs. 23.9 6 5.7% for 100 mg protein/ml n-LDL, p ,
0.01, Fig. 3). Relaxation to nitroprusside was not signifi-
cantly inhibited by n-LDL from control or diabetic men
(Fig. 4). There was an inverse correlation between the in
vivo response to acetylcholine (mean for all doses) and the
Figure 1. Forearm blood flow during brachial artery infusion of
acetylcholine (7.5, 15 and 30 mg/min) and nitroprusside (1, 3 and
10 mg/min) in healthy control men (n 5 10, open squares) and
men with type II diabetes (n 5 10, closed squares). p , 0.01 for
the comparison of blood flow responses to acetylcholine in men
with type II diabetes compared with those in control subjects by
ANOVA for repeated measures.
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degree of impairment (mean inhibitory effect for both
concentrations of LDL) of endothelium-dependent relax-
ation in vitro produced by isolated LDL (R 5 0.57, p ,
0.05).
DISCUSSION
Our findings that vasodilator responses to brachial artery
infusion of acetylcholine are impaired in men with type II
diabetes are in line with those of other investigators (3,4).
Responsiveness to nitroprusside was not impaired. Vasodi-
lator effects of acetylcholine in this vascular bed are medi-
ated, at least in part, through the stimulation of the
L-arginine/nitric oxide (NO) pathway within vascular en-
dothelium (13). Those of nitroprusside, which degrades
spontaneously to act as an NO donor or related vasodilator,
are mediated by the same effector mechanism but do not
involve elaboration of NO from the endothelium. The
present in vivo findings are thus most readily explained by
impaired formation or increased inactivation of
endothelium-derived NO in men with type II diabetes
compared with healthy control subjects. Some (3,4) but not
all (14) investigators have demonstrated impaired responses
to the nitrovasodilators glyceryl trinitrate or nitroprusside in
type II diabetes, in addition to impaired responsiveness to
acetylcholine. It is possible that these variable findings with
regard to nitrovasodilators relate to the characteristics of the
diabetic subjects particularly with regard to the duration,
control and presence of complications such as peripheral
neuropathy (15).
Previous in vitro studies have shown that n-LDL impairs
endothelium-dependent relaxation (11). In the present
study, we have examined the possibility that n-LDL from
men with type II diabetes is more potent in this regard than
that from control subjects. The major novel finding of the
study is that n-LDL from patients with type II diabetes
produced markedly greater inhibition of endothelium-
dependent relaxation to acetylcholine in a bioassay system
than did equal concentrations of n-LDL isolated from
control subjects. This suggests that a qualitative abnormality
of n-LDL is responsible, at least in part, for the endothelial
dysfunction seen in men with type II diabetes. By isolating
n-LDL and studying its effects ex vivo, we have distin-
guished effects of LDL from those of other lipoproteins (the
concentrations of which are often altered in type II diabe-
tes). This study, therefore, provides direct evidence that the
characteristics of LDL in type II diabetes are such as to
increase its potency in inhibiting endothelium-dependent
relaxation. Furthermore, since endothelial dysfunction is
thought to precede atherosclerosis (1,16), the results
strongly support the hypothesis that LDL in type II diabetes
is more atherogenic than is LDL from healthy nondiabetic
men. An interference supported by results from the 4S study
(17) is that patients with type II diabetes may benefit to an
Figure 2. Bioassay system to examine effects of n-LDL isolated
from men with type II diabetes (n 5 10, closed squares) and
control subjects (n 5 10, open squares) on endothelium-
dependent relaxation to acetylcholine (ACh) in rabbit aortic rings
preconstricted with noradrenaline. Relaxation in absence of
n-LDL is shown in open circles. p value refers to comparison of
inhibitory effects of n-LDL from men with type II diabetes with
those of n-LDL from control subjects by ANOVA for repeated
measures.
Figure 3. Inhibitory effects of n-LDL isolated from control men
(n 5 10, open bars) and men with type II diabetes (n 5 10,
shaded bars) on relaxation of rabbit rings to acetylcholine. Percent
inhibition refers to the difference between the sum of relaxations to
all doses to acetylcholine in the absence and presence of n-LDL. p
, 0.01 for the difference between effects of n-LDL from controls
and diabetics.
Figure 4. Effects of n-LDL isolated from men with type II
diabetes (n 5 10, closed squares) and control subjects (n 5 10,
open squares) on endothelium-independent relaxation to sodium
nitroprusside in rabbit aortic rings preconstricted with noradren-
aline. Relaxation in absence of n-LDL is shown in open circles.
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even greater degree than nondiabetic subjects from reduc-
tions in LDL cholesterol and that this benefit may extend to
diabetic patients with LDL cholesterol levels within the
conventional normal range. Furthermore, there may be
scope for interventions that modify the characteristics of
n-LDL to decrease its inhibitory actions on the endothe-
lium and hence its atherogenicity. Qualitative differences in
the injurious effects of LDL on the endothelium may exist
in non diabetic patients (for example, those with insulin
resistance) and may explain why, in patients with otherwise
similar risk factors, prediction of cardiovascular events from
the concentration of LDL cholesterol alone is of limited
precision.
There are a number of characteristics of LDL that are
altered in type II diabetes and that might potentially
account for its increased inhibitory actions on the endothe-
lium. These include the distribution of LDL in smaller
denser subfractions and the oxidation, glycosylation and
desialylation of LDL. The importance of small dense LDL
has received much attention because of experimental evi-
dence suggesting increased atherogenic potential of small
dense LDL and evidence, mainly in nondiabetic subjects,
that small dense LDL is associated with a higher incidence
of ischemic heart disease (6,18). In the present study, we
found that the LDL subfraction distribution and concen-
trations of triglycerides (closely related to LDL size) were
not significantly different in diabetic and control men. Thus,
although we did not measure absolute particle size, it is
unlikely that this differed in the diabetic and nondiabetic
men in this study. This is consistent with previous studies in
which the association of type II diabetes with LDL particle
size has been largely restricted to women, with only a weak
or nonsignificant association seen in men (19). It is unlikely,
therefore, that the increased inhibitory effects on
endothelium-dependent relaxation of the LDL from dia-
betic men in this study relates simply to altered LDL
particle size. Previous measurements of endothelial function
in vivo from our laboratory also suggest that particle size is
not the main determinant of endothelium-dependent vaso-
dilation in nondiabetic men. In a series of 50 men (24
studied in previously published studies [2,20]) with a range
of serum concentrations of LDL cholesterol of 72 to 240
mg/dl and triglycerides of 57 to 698 mg/dl, we observed a
strong correlation between the vasodilator response to
acetylcholine and total cholesterol (R 5 0.44, p , 0.01), but
no independent correlation with triglyceride concentration.
Oxidative stress is increased in type II diabetes and could
result in partial oxidation of LDL, which is known to alter
its properties in inhibiting endothelium-dependent relax-
ation (11). In the present study, LDL was collected into
EDTA to prevent oxidation, and TBARS were not detect-
able. The presence of any substantial degree of oxidation,
particularly that occurring ex vivo, was thus excluded. An
electronegative subfraction of LDL (LDL2) has been iden-
tified in plasma that exhibits minor degrees of oxidation and
is cytotoxic to endothelial cells (21). Concentrations of
circulating LDL2 may be elevated in type II diabetes (5),
possibly contributing to the increased inhibitory effects on
endothelium-dependent relaxation. Low-density lipopro-
tein in patients with diabetes may be glycosylated and may
contain less sialic acid than that from nondiabetic subjects
(5). Increased inhibitory actions of diabetic LDL on
endothelium-dependent relaxation may result from a com-
bination of altered physico-chemical properties such as an
increased proportion of electronegatively charged, glycosy-
lated and desialylated particles. Further studies will be
required to relate such properties of LDL to the impairment
of endothelium-dependent relaxation.
In conclusion, we have demonstrated that LDL isolated
from men with type II diabetes and endothelial dysfunction
is more potent in inhibiting endothelium-dependent relax-
ation than that isolated from control subjects. Qualitative
differences in the ability of LDL to injure the endothelium
may contribute to endothelial dysfunction and the increased
prevalence of atherosclerosis in type II diabetes. Interven-
tions to modify the characteristics of LDL may be of
importance in restoring endothelial function in type II
diabetes. Patients with type II diabetes may also benefit
from reduction of LDL cholesterol levels below the targets
set for nondiabetic patients.
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